arGEN X (1AE) Stock Price & Analysis

0 Followers

1AE Stock Chart & Stats

€886.40€11.80(1.35%)

At close: Nov 12 5:30 PM GMT+1

Day’s Range: EUR 874.60 - EUR 890.00
52-Week Range: EUR 574.20 - EUR 922.00
Previous Close: EUR 874.60
Volume: N/A
Average Volume (3M): 261
Market Cap: EUR 55.05B
Enterprise Value: EUR 47.77B
Total Cash (Recent Filing): EUR 3.26B
Total Debt (Recent Filing): EUR 37.70M
Price to Earnings (P/E): 46.1
Beta: 0.20
Next Earnings: Feb 25, 2027 (Est.)
EPS Estimate: 7.14
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

arGEN X News

Argenx price target lowered to $1,130 from $1,190 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Argenx (ARGX) to $1,130 from $1,190 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets among its

9h agoARGX 1AE

Roth Capital biotech analysts hold analyst/industry conference call

Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthus’ (DNTH) and Argenx’s (ARGX) December MMN results on an Analyst/Industry conference call to be held

2d agoARGX DNTH

Argenx to acquire Unnatural Products for $1.15B

Argenx (ARGX) announced a definitive agreement to acquire Unnatural Products, adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. Argenx, which already holds a minority stake in UNP,

4d agoARGX 1AE

argenx to Acquire Unnatural Products for Up to $1.15 Billion

arGEN X ( ($GB:0QW0) ) just unveiled an announcement. argenx agreed to acquire Unnatural Products, adding the biotechnology company’s macrocyclic peptide discovery platform to its antibody-engineering capabilities. The transaction values

4d ago1AE 0QW0

Weekend Fly By: Top five stock stories

Catch up on the weekend’s top five stories with this list compiled by The Fly: Nvidia (NVDA) said in a statement that its board is “initiating an independent investigation in

4d agoANT NVS

Argenx announces Phase 3 ALKIVIA study met primary, secondary endpoints

argenx (ARGX) announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART Hytrulo in patients with autoimmune myositis will be featured in a late-breaking

5d agoARGX 1AE

argenx Reports Positive ALKIVIA Phase 3 Results in Autoimmune Myositis

arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx SE is an immunology-focused biotechnology company developing antibody-based therapies for autoimmune diseases. Its portfolio includes VYVGART Hytrulo (efgartigimod alfa and

6d ago1AE 0QW0

argenx Management to Participate in Two November Healthcare Conferences

arGEN X ( ($GB:0QW0) ) just unveiled an announcement. argenx said members of its management team will participate in fireside chats at the Guggenheim Healthcare Innovation Conference on November 10

1w ago1AE 0QW0

Argenx price target lowered to $1,232 from $1,301 at Citi

Citi lowered the firm’s price target on Argenx (ARGX) to $1,232 from $1,301 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3

2w agoARGX 1AE

Argenx price target raised to $1,190 from $1,140 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Argenx (ARGX) to $1,190 from $1,140 and keeps an Overweight rating on the shares. Published first on TheFly –

3w agoARGX 1AE

Argenx price target lowered to $1,120 from $1,185 at Guggenheim

Guggenheim lowered the firm’s price target on Argenx (ARGX) to $1,120 from $1,185 and keeps a Buy rating on the shares despite the company having delivered what the firm calls

3w agoARGX 1AE

Argenx price target raised to $861 from $823 at Baird

Baird analyst Collen Kusy raised the firm’s price target on Argenx (ARGX) to $861 from $823 and keeps a Neutral rating on the shares. The firm updated its model following

3w agoARGX 1AE

Argenx price target lowered to $1,336 from $1,356 at Wells Fargo

Wells Fargo lowered the firm’s price target on Argenx (ARGX) to $1,336 from $1,356 and keeps an Overweight rating on the shares. The firm notes that the muted reaction reflects

3w agoARGX 1AE

Argenx posts surging VYVGART sales as immunology pipeline advances toward Vision 2030

arGEN X ( ($GB:0QW0) ) just unveiled an announcement. Argenx reported a strong third quarter, with VYVGART driving $1.7 billion in global product net sales, up 54% year over year

3w ago1AE 0QW0

1AE FAQ

What was arGEN X’s price range in the past 12 months?

arGEN X lowest stock price was €574.20 and its highest was €922.00 in the past 12 months.

What is arGEN X’s market cap?

arGEN X’s market cap is €55.05B.

When is arGEN X’s upcoming earnings report date?

arGEN X’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 104 days.

How were arGEN X’s earnings last quarter?

arGEN X released its earnings results on Oct 22, 2026. The company reported €6.966 earnings per share for the quarter, missing the consensus estimate of €7.084 by -€0.118.

Is arGEN X overvalued?

According to Wall Street analysts arGEN X’s price is currently Undervalued.

Does arGEN X pay dividends?

arGEN X does not currently pay dividends.

What is arGEN X’s EPS estimate?

arGEN X’s EPS estimate is 7.14.

How many shares outstanding does arGEN X have?

arGEN X has 62,886,074 shares outstanding.

What happened to arGEN X’s price movement after its last earnings report?

arGEN X reported an EPS of €6.966 in its last earnings report, missing expectations of €7.084. Following the earnings report the stock price went up 0.077%.

Which hedge fund is a major shareholder of arGEN X?

Currently, no hedge funds are holding shares in DE:1AE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

arGEN X

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.

arGEN X (1AE) Earnings & Revenues

Historic Earnings Reports

1AE Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was strongly constructive, led by 54% year-over-year product sales growth, continued patient and prescriber expansion for VYVGART, positive ALKIVIA and FB102 data, a broadening clinical pipeline and up to five potential launches in 2027. The principal setbacks were the dermatomyositis primary-endpoint miss, the Sjögren’s futility decision, the discontinued TED program and materially higher planned operating expenses. Management nevertheless expressed confidence in Vision 2030 and emphasized continued margin expansion and investment from a position of financial strength.

View all DE:1AE earnings summaries

1AE Stock 12 Month Forecast

Average Price Target

€933.80▲(5.35% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High€1K

Average€933.80

Low€850.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	14	2	6
Technical Analysis	2	2	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to DE:1AE
Company	Price & Change	Follow
GB:0QW0arGEN X
GB:AVCTAvacta Group plc
GB:EKFEKF Diagnostics Holdings

Compare DE:1AE Stocks >

Ownership Overview

10.73% Mutual Funds
<0.01% Other Institutional Investors
73.08% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

1AE Stock Chart & Stats

arGEN X News

Argenx price target lowered to $1,130 from $1,190 at Morgan Stanley

Roth Capital biotech analysts hold analyst/industry conference call

Argenx to acquire Unnatural Products for $1.15B

argenx to Acquire Unnatural Products for Up to $1.15 Billion

Weekend Fly By: Top five stock stories

Argenx announces Phase 3 ALKIVIA study met primary, secondary endpoints

argenx Reports Positive ALKIVIA Phase 3 Results in Autoimmune Myositis

argenx Management to Participate in Two November Healthcare Conferences

Argenx price target lowered to $1,232 from $1,301 at Citi

Argenx price target raised to $1,190 from $1,140 at Morgan Stanley

Argenx price target lowered to $1,120 from $1,185 at Guggenheim

Argenx price target raised to $861 from $823 at Baird

Argenx price target lowered to $1,336 from $1,356 at Wells Fargo

Argenx posts surging VYVGART sales as immunology pipeline advances toward Vision 2030

1AE FAQ

Company Description

arGEN X

arGEN X (1AE) Earnings & Revenues

1AE Earnings Call

Earnings Call Sentiment|Positive

1AE Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive